Skip to content
Sign in

Business opportunities

Who each startup should sell to, sell through, build with, enter a market with or raise from, read from the whole network. Every opportunity comes with its reasoning, the evidence and a first step.

SWC 2026 Finalist

StemSight

Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.

Open the dossier
Opportunities
4
High confidence
070% and above
Counterparts
4startups and investors
  • Customers 1
  • Co-development 2
  • Investors 1

Customers1

Who could buy, or sell through

Qualify defined, serum-free media for StemSight's manufacturing process

Moving iPSC-derived cells to the clinic requires defined, low-variability media; Defined Bioscience sells exactly this for pluripotent stem cells. A supply and co-development agreement lowers StemSight's cost of goods and gives Defined Bioscience a clinical-pathway customer.

40%confidence

Evidence from the records

  • “Fully defined media formulations with stabilized growth factors, reducing the cost and variability of stem cell culture.”
  • “Corneal cells derived from induced pluripotent stem cells (iPS); clinical trials targeted around 2027.”
  • “patent granted in Singapore (June 2026) for its scalable stem cell technology.”
If it works
Lower manufacturing cost and a qualified supplier for the clinical process.
First step
Request HiDef-B8 samples and run a comparison against current media.

Co-development2

An integration or joint product

Use portable corneal topography for patient selection and trial endpoints

Corneal cell-therapy trials need objective corneal-surface measurements; Ocuwell's handheld device delivers topography comparable to reference machines. Using it in StemSight trials helps standardise endpoints and gives Ocuwell clinical-trial use.

25%confidence

Evidence from the records

  • “OCUTOP: handheld device providing corneal topography data equivalent to reference machines, with cloud solutions.”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
If it works
A trial-endpoint partnership and joint publications.
First step
Organise a call between the two clinical teams on endpoint needs.

Explore polymer carriers for corneal cell delivery

Cell sheets need carriers or injectable biomaterials; Pleryon designs ophthalmic polymer biomaterials and is in first-in-human for dry eye. A feasibility study could improve cell engraftment.

15%confidence

Evidence from the records

  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
  • “Scalable corneal cell therapy: a new approach for a form of blindness with no satisfactory treatment.”
If it works
A material-transfer agreement and feasibility data.
First step
Send Pleryon a carrier specification and ask about MTA terms.

Investors1

A fund whose thesis fits

Apply to the EIC for clinic-entry funding

The EIC funds breakthrough biotech in Europe from seed with grants and equity, and the cash need to reach the clinic suits its risk appetite. EIC-backed network members (Lampsy Health, Leitspalt) can share learnings.

35%confidence

Evidence from the records

  • “Close the funding gap for breakthrough technologies in Europe by taking strategic risk and crowding in private capital.”
  • “High risk: long clinical and regulatory path, US$3M raised.”
If it works
Grant plus equity to fund GMP and the first trial.
First step
Book a pre-submission coaching session and draft the EIC short proposal.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai

Most promising across the network

587 opportunities analysed
  1. BelliwithGolden Gate VenturesInvestors
    Pitch Series A to an Asia–Middle East early-stage VC

    Belli's revenue base sits exactly in Golden Gate's footprint: Singapore HQ, Southeast Asian carriers and Gulf flag carriers. Golden Gate invests Seed to Series A, the stage Belli is approaching, and already backed BioSapien in the network, which gives a warm founder-to-founder introduction.

    50%
  2. AstrolightwithSeraphim SpaceInvestors
    Series A from a specialist space investor

    Seraphim invests globally in space and deep tech addressing security and resilience, from Seed onwards, and appears among G-Space's investors in the network. Astrolight's dual-use optical links fit that thesis precisely.

    40%
  3. ChonexwithCavallo VenturesInvestors
    Bring an agri CVC into the Series A

    Cavallo Ventures is an agri-focused CVC investing from seed to Series B and backed network member ZymoChem. A strategic agri investor fits Chonex's $6M Series A and can accelerate distribution.

    40%
  4. CredncewithMicrotractionInvestors
    Pitch a pre-seed fund whose ticket matches the round

    Crednce is raising $175,000; Microtraction writes $0.1–0.35M pre-seed tickets in Africa with FinTech in its sectors and Ghana in its geographies. The ticket and stage fit are exact, which is rare for a pre-traction fintech.

    40%
  5. TerraSparkwithSeraphim SpaceInvestors
    Target Seraphim Space for the seed round

    Seraphim invests globally in space and climate deep tech from seed onward, with a resilience thesis that covers energy security. It backed network member G-Space, giving a warm path to a seed lead after the 2026 demonstration.

    40%
  6. Thistle OÜwithNATO DIANAInvestors
    Apply to NATO DIANA with the trial results

    NATO DIANA supports pre-seed and seed dual-use start-ups across Europe and North America, exactly Thistle's stage. Network member Astrolight is in the DIANA programme and can coach the application.

    40%
  7. VenditekwithInnogen Capital VenturesInvestors
    Raise from Innogen Capital via Pulster

    Innogen invests at pre-seed and seed in commerce and retail across El Salvador, Honduras, Guatemala and Latin America. It backed network member Pulster.ai, a warm path and a natural co-operation story.

    40%
  8. Wink BiotherapeuticswithU.S. National Institutes of Health (NIH)Investors
    Apply for NIH SBIR funding

    NIH funds US biotech and medtech via SBIR and backed network members Defined Bioscience, Corticale and Microvitality. Non-dilutive funding fits Wink's $75K capital base.

    40%
  9. General Ammonia Co.withU.S. Department of Energy (DOE)Investors
    Apply for DOE early-stage funding via the Sunchem path

    DOE funds pre-seed and seed climate and deep tech in the US, the natural first money for a lab-to-pilot electrochemistry project. DOE already supports network members Sunchem, ZymoChem and Enexor; Sunchem went through Cyclotron Road / DOE LEEP and can advise on the route.

    40%
  10. Neumic Therapeutics LtdwithIcehouse VenturesInvestors
    Seed round from New Zealand's early-stage investor

    Icehouse invests early in Kiwi founders and keeps backing them internationally, from pre-seed to later stages, and backed Neocrete in the network. A University of Otago spin-off with a Volpara co-founder is squarely in its remit.

    40%
  11. IKI HealthwithMutua Ventures (Mutua Madrileña)Investors
    Pitch Mutua Ventures on prevention for an insurer

    Mutua Ventures is the Spanish insurer-backed CVC investing in HealthTech in Spain and Europe and backed network member Legit.Health. A prevention platform with clinical data matches an insurer's interest in reducing claims.

    40%
  12. Piezo Sonic CorporationwithSBI InvestmentInvestors
    Pitch SBI Investment for a disclosed growth round

    SBI Investment's stated focus covers robotics and hardware at Series A and later in Japan and Asia, matching Piezo Sonic's stage and geography. SBI already backed network member Kauche, which gives a warm intro path inside Champions Network.

    40%
  13. Allergen AlertwithEuropean Innovation Council (EIC / EIC Fund)Investors
    EIC Accelerator for diagnostic deep tech

    The EIC Fund takes strategic risk on European breakthrough MedTech/deep tech from seed, with tickets from $0.55M. Allergen Alert's pre-commercial, hardware-heavy profile is exactly the funding gap it targets; network members Lampsy Health and Leitspalt are EIC-backed and can share application experience.

    35%
  14. AstromewithSeraphim SpaceInvestors
    Pitch Seraphim for the Series A

    Seraphim invests globally in space and deep tech for security and resilience from seed onward. It backed network member G-Space, giving a warm path as Astrome moves into satcom.

    35%
  15. TausiwithAntler East AfricaInvestors
    Pitch Antler East Africa for a pre-seed cheque

    Antler East Africa invests up to $0.1M at pre-seed in East Africa; the global Antler network backed network members ThirdRoc and aimea.ai.

    35%
  16. TerraSparkwithEuropean Innovation Council (EIC / EIC Fund)Investors
    Prepare an EIC Accelerator blended-finance bid

    The EIC Fund backs European breakthrough technologies in space and climate with tickets from €0.5M up to €33M, matching TerraSpark's capital intensity. Network members Leitspalt and Lampsy Health obtained EIC support and can share application know-how.

    35%
  17. Thistle OÜwithCoinvest CapitalInvestors
    Bring Coinvest Capital into the open round

    Coinvest is a Lithuanian pre-seed/seed fund investing in deep tech, robotics and AI across Europe, and it backed network member Astrolight, a dual-use company. A Baltic investor familiar with defence suits Thistle's open first round.

    35%
  18. TRL11withSeraphim SpaceInvestors
    Space-specialist investor for the next round

    Seraphim invests from Seed in space ventures addressing security and resilience globally and is listed among G-Space's investors in the network. TRL11's SSA and RPO imaging fits security-oriented space infrastructure.

    35%
  19. EvoNaturawithSOSVInvestors
    Pitch SOSV, ZymoChem's early backer

    SOSV backs deep tech for planetary health from pre-seed onwards and supported ZymoChem through IndieBio in the network.

    35%
  20. EVR Motors Ltd.withBorgWarnerInvestors
    Strategic investment from an EV drivetrain tier-1

    BorgWarner invests strategically in Mobility and Climate & energy and made a $10M strategic minority investment in Enexor in the network. A compact, low-rare-earth motor topology is directly relevant to a drivetrain supplier, and EVR's Series A is announced as under way.

    35%

Similar profiles

Compatibility score with StemSight

Scored on needs and offers, market bridge, customer potential, sector synergy and stage. Open a profile to see each dimension.